Purpose: Amidst the ongoing coronavirus disease 2019 (COVID-19) pandemic, India experienced an epidemic of COVID-19-associated rhino-orbito-cerebral mucormycosis (ROCM). This study aimed to describe the epidemiology and elucidate the risk factors for developing COVID-19-associated ROCM, comparing the risk factors among COVID-19 patients with and without ROCM.
Methods: This case-control study included all COVID-19-associated ROCM patients treated at our hospital from May 1 to July 30, 2021. Controls included age- and sex-matched COVID-19 patients without ROCM, who were treated during the same time (exact matching, in 1:2 ratio). Matched pair analysis using conditional logistic regression was performed to examine the association of various risk factors with the development of ROCM in COVID-19 patients.
Results: The study included 69 patients with COVID-19-associated ROCM and 138 age- and gender-matched controls. Epidemiologically, COVID-19-associated ROCM predominantly affected males (59/69, 85%), in their early 50s (mean 52 years), with 48% (33/69) of patients being from medical resource-constrained settings. On multivariate conditional logistic regression, elevated serum glycated hemoglobin (HbA1c) (odds ratio [OR] = 1.36, 95% confidence interval [CI]: 1.03-1.78), blood glucose (OR = 1.008, 95% CI: 1.003-1.013), and C-reactive protein (CRP) (OR = 1.07, 95% CI: 1.02-1.17) were associated with increased odds of developing COVID-19-associated ROCM. Patients with undetected diabetes mellitus with increasing HbA1c (OR = 3.42, 95% CI: 1.30-9.02) and blood glucose (OR = 1.02, 95% CI: 1.005-1.03) (P = 0.02) had a higher probability of developing COVID-19-associated ROCM than patients with established DM.
Conclusion: Uncontrolled DM evidenced by elevated HbA1c and blood glucose levels, exacerbated by COVID-19-induced proinflammatory state indicated by elevated CRP, is the principal independent risk factor for COVID-19-associated ROCM. Middle-aged males with undetected DM, from a resource-constraint setting, are particularly at risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672762 | PMC |
| http://dx.doi.org/10.4103/ijo.IJO_448_22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MR Imaging in Covid-19-Associated Invasive Fungal Sinusitis.
Neurol India
September 2024
Department of Radiology, Krishna Institute of Medical Sciences, Secunderabad, Telangana, India.
Article Synopsis
- - The study focuses on the rise of invasive fungal sinusitis, particularly mucormycosis, in post-COVID-19 patients in India, highlighting the importance of early diagnosis through neuroimaging to improve survival rates.
- - Researchers analyzed MR imaging from 91 confirmed cases, finding that over half of the patients (51.6%) had advanced disease with intracranial spread, with significant complications such as cavernous sinus involvement and osteomyelitis.
- - The results showed that unlike non-COVID-19 cases, there were no instances of certain severe complications like thrombosis in the studied COVID-19-associated cases, emphasizing unique patterns in disease manifestation.
Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients.
J Assoc Physicians India
October 2024
Associate Professor, Department of Microbiology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India.
Article Synopsis
- The study investigated 69 COVID-19 patients with mucormycosis, focusing on their clinical presentation, risk factors, complications, and in-hospital results over seven months from March to September 2021.
- The majority of patients were male, around 52.8 years old, with most developing mucormycosis within 30 days of COVID-19; common symptoms included facial pain and vision loss, and diabetes was prevalent in 98.6% of cases.
- The overall mortality rate was 26.1%, with severe cases requiring intensive care linked to factors such as chronic kidney disease and current COVID-19 infection, indicating a heightened risk for these patients.
COVID-19-associated rhino-orbito-cerebral mucormycosis: a single center prospective study of 264 patients.
Orbit
July 2024
Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut, USA.
Purpose: Outbreaks of mucormycosis were reported worldwide throughout the COVID-19 pandemic. We report clinical outcomes of a treatment protocol for COVID-19-associated rhino-orbital-cerebral mucormycosis (ROCM).
Methods: Patients with biopsy-proven mucormycosis and COVID-19 were included.
Utility of Itraconazole in Combination with Liposomal Amphotericin B in Rhizopus oryzae Associated Mucormycosis-An Exploratory Study.
Mycopathologia
June 2024
Department of Otorhinolaryngology, King George's Medical University, Lucknow, India.
Background: During the COVID-19 pandemic-associated mucor epidemic, acute antifungal drug shortage necessitated the exploration of other antifungals based on culture sensitivity. Itraconazole is a cheap, safe, and effective antifungal in sensitive cases.
Methodology: We enrolled itraconazole-sensitive COVID-19-associated mucormycosis during the mucormycosis pandemic.
C-reactive Protein Kinetics During In-Patient Treatment of COVID-19-Associated Rhino-Orbito-Cerebral Mucormycosis: A Retrospective Cohort Study in a Tertiary Hospital in Central India.
Cureus
April 2024
Anatomy, All India Institute of Medical Sciences, Bibinagar, Hyderabad, IND.
COVID-associated rhino-orbito-cerebral Mucormycosis (CA-ROCM), henceforth referred to as Covid-Associated Mucormycosis (CAM), is a serious and fatal condition unless treated promptly and completely. The main treatment of the CAM is complete surgical debridement and administration of systemic antifungals. The first line antifungal recommended for CAM is Amphotericin-B.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!